Researchers successfully conjugated resveratrol to cashew allergens using ascorbic acid and hydrogen peroxide, achieving a 49% increase in β-turn protein structure that reduced allergenic binding potential. The modified proteins showed decreased reactivity to both anti-cashew IgG and human sIgE antibodies while maintaining biocompatibility up to 1000 μg/mL in cell tests. Additionally, the conjugates suppressed TNF-α-induced IL-8 secretion, demonstrating anti-inflammatory properties. This represents a potentially transformative approach to food allergy treatment. Traditional oral immunotherapy carries substantial risk because it uses unmodified allergens that can trigger severe reactions. By chemically modifying the allergen structure while preserving therapeutic potential, this strategy could make immunotherapy significantly safer for the estimated 1% of adults with tree nut allergies. The dual benefit of reduced allergenicity plus anti-inflammatory action from resveratrol creates a compelling therapeutic profile. However, this is early-stage laboratory research using cell cultures rather than human subjects. Clinical translation will require extensive safety and efficacy testing, particularly given the life-threatening nature of severe food allergies. Still, the structural modification approach represents innovative thinking that could reshape allergy treatment paradigms.